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Abstract
There is currently no standardized method for reporting au-
diological, surgical and subjective outcome measures in clin-
ical trials with active middle ear implants (AMEIs). It is often 
difficult to compare studies due to data incompatibility and 
to perform meta-analyses across different centres is almost 
impossible. A committee of ENT and audiological experts 
from Germany, Austria and Switzerland decided to address 
this issue by developing new minimal standards for report-
ing the outcomes of AMEI clinical trials. The consensus pre-
sented here aims to provide a recommendation to enable 
better inter-study comparability. © 2018 The Author(s)
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Introduction
Since its formation in 2008, the HEARRING network 
has established quality standards for hearing implants, 
specifying the resources that are required for clinical 
practice as well as the necessary aspects of providing the 
best care from patient referral and selection up to long-
term follow-up and maintenance. HEARRING consists 
of a group of leading experts in the field of hearing im-
plants who “are committed to leading the exploration of 
new avenues of research in hearing implant science, to 
advancing clinical procedures and to developing and per-
fecting surgical techniques” (http://www.hearring.com). 
Quality standards are now available for cochlear implants 
(CI), Electro-Acoustic Stimulation (EAS) systems, (ac-
tive) middle ear implants ([A]MEIs) and bone conduc-
tion implants (BCIs) [Godey, 2013; Hagen, 2013; Martin 
and Raine, 2013]. However, these standards focus mainly 
on improving clinical practice but provide limited infor-
mation about the essential audiological data set of results 
and how they should be reported. In order to identify a 
common ground for international multicentre research 
and collaboration, HEARRING members reached a con-
sensus on minimal outcome measurements, mainly for 
CI [Kleine Punte and Van de Heyning, 2013]. An equiva-
lent consensus on active middle ear implants (AMEIs) is 
lacking.
Middle ear implants are emerging as an important 
treatment option, with results being reported from vari-
ous sites, each with limited numbers of cases. This situa-
tion is even more complicated by the fact that AMEIs 
have been successfully used in dysfunctional middle ears 
with different coupling modalities to residues of the os-
sicular chain, the cochlear windows or even artificially 
created windows. While competent judgement and statis-
tically sound evidence require pooling data from different 
sources, this is currently difficult or impossible with the 
heterogeneous sets of data being reported. Defining a 
core dataset that can be extended according to the spe-
cific needs of the investigated application would enable 
comparison and pooling of results to create convincing 
evidence in meta-analyses. Ultimately, the outcome will 
be differential, better defined indication criteria as well as 
the possibility for cross-site comparison and determina-
tion of long-term results.
A minimal reporting standard for the full range of 
hearing loss treatments was introduced by the AAO-HNS 
Hearing Committee but does not include key parameters. 
Although defined as standard for reporting in several in-
ternational peer-reviewed ENT journals, the required re-
sults do not reflect the dataset necessary to allow differ-
entiated conclusions about the risks and treatment suc-
cess with AMEIs. Minimum outcome measures to be 
reported included air conduction (AC) pure tone thresh-
olds and word recognition scores (WRS) only [Gurgel et 
al., 2012]. These two measures are important to deter-
mine the success of a treatment but do not sufficiently 
facilitate detailed statistical analysis to provide conclusive 
evidence. In addition, the proposed WRS measure (40 dB 
above sensation level, SL) is not uniformly accepted, and 
the suggested form of a matrix plot hinders effective sam-
ple size calculations for planning clinical trials. Moreover, 
AC thresholds and WRS alone are not enough to make 
regulatory decisions, since the safety of the procedure and 
an improvement in the patient’s quality of life (QoL) need 
to be considered as well. Furthermore, the way adverse 
events (AEs) and QoL measures are reported in studies 
differs widely. Many systematic reviews on these topics 
have been unable to pool results and to carry out meta-
analyses due to heterogeneity of data [Bond et al., 2009; 
Colquitt et al., 2011; Johnson et al., 2006; Klein et al., 2012; 
2013]. Determining reporting standards for these out-
come measures would not only allow clinicians to com-
pare patients’ results to optimize their practice but would 
also aid manufacturers by the creation of sufficient data 
to gain and maintain market approval. Additionally, pol-
icy makers would be better able to make comparisons be-
tween devices and decide about reimbursement strate-
gies.
Scope
In regard to the issues mentioned above, the following 
consensus was established by a group of ENT and audio-
logical experts from Germany, Austria and Switzerland. 
The paper comprises minimal reporting standards on 
safety, surgical, audiological and QoL outcomes for 
AMEIs. Although designed initially for the assessment of 
German speaking subjects, the simplicity of this proposal 
makes it easily extendable to other languages. 
These recommendations refer to AMEIs, which con-
sist of all active, partially or totally implantable hearing 
implants in which the vibratory output drives any part of 
the middle ear including the ossicles or the bordering an-
atomical structures to the inner ear, namely, the round 
window or the perforated or unperforated stapes foot-
plate. These AMEIs can treat sensorineural, conductive 
or mixed hearing losses.
Although these recommendations do not, in principle, 
extend to implantable bone conduction devices in which 
vibrations are delivered to the skull outside of the middle 
Minimal Reporting Standard AMEI 107Audiol Neurotol 2018;23:105–115
DOI: 10.1159/000490878
ear, we would like to point out that they can also be ap-
plied to most applications of this group of devices. How-
ever, these recommendations explicitly do not extend to 
the application of single-sided deafness.
These standards aim to provide the researcher with a 
list of tests a study should cover to ensure comparability 
of results and acceptance by the wider research commu-
nity. Review boards would be able to improve the quality 
of AMEI-related publications by applying these stan-
dards as criteria to evaluate articles. Manufacturers who 
implement these minimal standards will be able to ensure 
that data are comparable across studies, enabeling the 
pooling of data. In addition, the minimal reporting stan-
dards proposed here cover information that has to be ob-
tained as a basis for regulatory decision-making and 
which was missing in the previously published reporting 
standards [Gurgel et al., 2012].
Our recommendations for minimal reporting stan-
dards focus on the performance of the device, the risks and 
benefits for the patient and the patient’s quality of life. 
Three different approaches were incorporated to fulfill 
this: (1) For the description of procedure-specific proper-
ties, surgical information has to be reported. (2) The de-
vice performance should be assessed via audiological tests 
as described, initially monaurally. The focus was put on 
monaural evaluation, as we consider a framework that al-
lows for the collection of device- and application-specific 
data to be the priority. This enables the generation of de-
vice-relevant technical meta-data and does not question 
the importance of binaurally-determined results that bet-
ter reflect the impact on the patient’s life and can be as-
sessed optionally. (3) As the questionnaires also encom-
pass the binaural input in daily life, the focus is here on the 
individual real-world experience and quality of life.
Methods
Initiated by MED-EL Inc. (Innsbruck, Austria), a 
group of clinical specialists and researchers from Germa-
ny, Austria and Switzerland was formed. Surgeons (n = 
11) and audiologists (n = 8) were included in order to en-
compass all important aspects of AMEIs for reporting 
standards. Most of the participants were members of na-
tional or international audiological societies (ADANO, 
EFAS, DGA or EAONO), including board members. 
However, the initiative here was driven by individuals 
and no official mandate was sought. 
The participants recognize that the AMEI field is 
evolving rapidly and is likely to continue to advance fur-
ther. One clearly declared aim was therefore to generate 
recommendations which are useful and applicable to all 
current and future AMEIs, strictly independent of any 
specific device or manufacturer. The “World Café” meth-
odology [Fouché and Light, 2011; Stewart, 2005] was used 
to form consensus-driven agreement on reporting stan-
dards covering the topics of medical and surgical proce-
dures, as well as audiological, safety and subjective out-
comes.
Reporting of Outcomes
Stakeholders identified a core group of minimal stan-
dards they considered to be essential to report when pub-
lishing data on AMEIs. For practicality, the outcomes are 
divided into pre- and post-operative procedures.
Demographics
A table containing patient demographics including 
etiology and previous surgical interventions should be in-
cluded. Usage of hearing devices before AMEI implanta-
tion should also be reported in this table. Inclusion of 
patients with indications for devices outside of the in-
tended use by the manufacturer needs to be clearly men-
tioned with a short explanation about the reasons behind 
this. 
Medical and Surgical Reporting Standards
Hearing rehabilitation outcomes with an AMEI are re-
lated to the underlying medical problem, that is otological 
and audiological and the implantable hearing system 
used, as well as the surgical procedures undertaken. There 
are various surgical methods used both to address the 
otological disease in general and to couple the AMEI to 
the inner ear for energy transfer. While disease classifica-
tion and staging and description of the surgical procedure 
is very similar to conventional middle ear and temporal 
bone surgery, some aspects are specific to the usage of 
AMEIs for hearing rehabilitation.
Reporting of Preoperative Characteristics
Data should be reported for individual patients (see on-
line suppl. Table 1; for all online suppl. material, see www.
karger.com/doi/10.1159/000490878 for version 1.0 (up-
dated versions can be found at https://cdn.hno.org/me-
dia/publikationen/minimal_standards_for_AMEI_
v1.0.xlsx and https://www.dga-ev.com/fachausschuesse/). 
This enables significantly more valuable data extraction 
for systematic reviews and meta-analysis. 
Maier et al.Audiol Neurotol 2018;23:105–115108
DOI: 10.1159/000490878
The general medical/otological diagnosis should be 
described/classified, as well as the patient’s indication for 
an AMEI, that is, the medical or audiological condition 
that makes hearing rehabilitation with a conventional 
hearing aid impossible or insufficient. This comprises the 
following conditions, among others: chronic otitis media, 
chronic adhesive otitis media, cholesteatoma, mastoid-
itis, sclerotic middle ear disease (tympanosclerosis, mid-
dle ear fibrosis), otosclerosis, traumatic ossicular chain 
disruption, chronic ear canal infection, recurrent post-
inflammatory meatal fibrosis, eczema of the ear canal, 
chronic ear canal pain or middle ear/ear canal malforma-
tion.
Many patients have had multiple previous surgeries, 
and the number of surgeries and specifics about the re-
spective ear should be stated (e.g., present open mastoid 
cavity, labyrinthine fistula of the oval window or stapes 
footplate fracture, wide exposure of the dura etc.).
In cases of malformation, the important aspects of the 
malformation should be described, especially with re-
spect to pneumatization and/or size of the mastoid, the 
patient’s ear canal, the round and oval windows, the os-
sicles and the course of the facial nerve. 
The Jahrsdoerfer and Siegert scores [Jahrsdoerfer et 
al., 1992; Siegert et al., 1996], developed before AMEIs 
existed, are more relevant to conventional middle ear sur-
gery in patients with malformations. The AMEI score, 
however, should be reported as this score allows for a 
more specific assessment of the probability of success 
with an AMEI [Frenzel et al., 2013].
Reporting of Surgical and Medical Characteristics
Reporting standards from conventional middle ear 
and temporal bone surgery contain descriptions of surgi-
cal procedures based on the underlying otological prob-
lem [American Academy of Otolaryngology – Head and 
Neck Surgery Foundation, 1995; Becvarovski and Kar-
tush, 2001; Bellucci, 1989; Dornhoffer and Gardner, 2001; 
Neudert and Zahnert, 2017; Tos, 2008].
AMEI surgery requires the following minimum infor-
mation related to the surgical procedure to be reported: 
canal wall up with or without posterior tympanotomy, 
canal wall down, extent of mastoid obliteration or poste-
rior canal reconstruction in canal wall down techniques, 
materials for tympanic membrane reconstruction (carti-
lage, fascia, perichondrium or compound transplants), 
lateral petrosectomy and external ear canal closure.
It is important to precisely state the method used to 
couple the AMEI to the inner ear in order to evaluate the 
quality of energy transfer. Information on whether the 
AMEI was coupled to the middle ear structure, to the in-
ner ear fluids via the round window- or oval window 
membrane or directly into the fluid, should be included. 
If coupling elements are used, they must be mentioned. If 
coupling elements are altered or “custom made” by the 
surgeon to fit the specific anatomical situation, this should 
be mentioned and identified as “off label use” or “non-
approved”. If additional measures, for example, “lifts” for 
active bone conduction implants, are used, this should be 
stated. If applicable, the placement of an implant cable 
should be specified.
The presence or absence of intraoperative or postop-
erative problems and complications must be reported for 
at least the first 6 months (the audiological observation 
period); for example, complications such as ossicle luxa-
tion, labyrinthine fistula, bleeding, liquorrhea, bacterial 
infection of the middle ear or the implant bed, labyrinthi-
tis, acoustic trauma or other sensorineural hearing loss ( 
(BC) thresholds, see below), vertigo, tinnitus, facial nerve 
injury, dysgeusia (affection of chorda tympani) dura or 
sinus conflicts including impression of structures, intra-
cranial complications (bleeding, infection, abscesses) and 
complications in wound healing or skin irritation at the 
incision or implant site need to be reported. Late compli-
cations, (1 year or more postoperative) including implant 
or wire extrusion, dislocation of transducer/coupler as-
sembly and loss of coupling (e.g., increase in in situ 
thresholds) need to be reported, as well as technical com-
plications and device failures. If a revision surgery was 
necessary, it must be stated whether it was due to medical/
surgical (procedure) or device-related reasons [Ernst et 
al., 2016; Gavilan et al., 2015; Hobson et al., 2010; Las-
saletta et al., 2016; Mohamad et al., 2016; Van Rompaey 
et al., 2011; Wazen et al., 2011; Zwartenkot et al., 2016].
Reporting Standards for Fitting
Various well-defined standards for the adjustment of 
frequency-specific amplification settings (fitting) exist 
for conventional hearing aids. Commonly used indepen-
dent fitting rules include NAL-NL1 or DSL I/O and com-
pany-specific fitting algorithms may add a “flavor” to de-
fine output targets for a specific input level. However, the 
situation for AMEIs is more complicated because the out-
put strongly depends on the coupling type chosen and 
varies substantially among individuals. We suggest mini-
mally reporting on the following:
• Which settings (e.g., company default, best threshold, 
max. output) were used.
• Whether or not a compression was used or temporar-
ily switched off for the determination of thresholds.
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As the intention of this paper was to define minimum 
standards, we limited the essential descriptors for fitting 
to a few basic ones that are independent of available 
equipment. Nevertheless, as fitting is crucial for any kind 
of hearing aid, we encourage reporting beyond the min-
imum. Here it may be important to include, for example, 
whether a systematic approach for fine tuning, (e.g. Sca-
lAdapt [Pastoors et al., 2001]) or if a virtual or real-life 
environment optimization was used. Reporting per-
formed post-fitting controls such as loudness scaling 
(e.g. ACALOS [Brand and Hohmann, 2002]) could fur-
ther complete the description of the fitting. Technical 
features determined during fitting, for example, if the 
uncomfortable levels were reached by the device or if 
gain was limited by feedback can provide valuable infor-
mation on maximum power output (MPO) and limita-
tions.
Audiological Outcomes
Table 1 shows the minimal set of audiological tests 
necessary for reporting outcomes obtained with AMEIs. 
Detailed information about each test is mentioned in the 
corresponding sections of this paper. For the reliability 
of post-op results, it is essential that the patients already 
obtained stable audiological results, which normally can 
be expected at 6 months after device activation. Howev-
er, if stable fitting is not achieved within that period, 
post-op results should be reported at least 1 month after 
it occurs.
In addition, documentation of (daily) device usage 
should be gathered either from the patient or preferably 
from data logging to report on how intensively the device 
was used or whether it was used at all.
Pure-Tone Audiometry
Pre-Op Procedures: Clinical pure-tone audiometry 
with headphones or insert earphones should be measured 
for each ear separately using adequate masking on the 
contralateral side. The AC thresholds from 0.25 to 8 kHz 
(0.25, 0.5, 1, 2, 4, 6 and 8 kHz) and BC thresholds from 
0.5 to 6 kHz (0.5, 1, 2, 4, and 6 kHz) should be reported 
as frequency-specific averages (mean, median) with ap-
propriate statistical descriptors (N’s, standard deviations 
or percentile ranges).
The individual audiological data should be presented 
in separate tables at the end of the manuscript (e.g., as 
Table 1. Measuring scheme for minimal reporting standards for AMEI devices
Audiological tests Pre-op At least 6 months
post-activation
Headphones or bone 
conduction headset
Pure-tone audiometry 
AC (0.25–8 kHz) and  
BC (0.5–6 kHz)
Bilaterally At least from implanted side
Speech audiometry 
(WRS at 65 and 80 dB SPL/ 
if necessary WRSmax)
At least from implanted side
(optional: bilaterally)
Sound field Sound field thresholds
(0.25–8 kHz) 
Unaided: ear to be implanted
(optional: with optimized HA1 
in the ear to be implanted)
Unaided: implanted ear2
AMEI aided: implanted ear
Sound field speech audiometry  
in quiet
(WRS at 65 dB SPL)
Unaided: ear to be implanted
(optional: with optimized HA1  
in the ear to be implanted)
Unaided: implanted ear2
AMEI aided: implanted ear
Sound field speech audiometry 
in noise
(SRT50, adaptive, S0N0, fixed noise  
at 65 dB SPL)
Unaided: ear to be implanted
(optional: with optimized HA1  
in the ear to be implanted)
Unaided: implanted ear
AMEI aided: implanted ear
1 An optimized HA is defined as a hearing aid deemed adequate for the current hearing loss and with controlled and optimized fit-
ting. 2 If there is a change between pre- and post-op pure tone thresholds at any frequency, the unaided setting must be measured and 
reported as well.
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online suppl. material Table 1, see www.karger.com/
doi/10.1159/000490878 for version 1.0 (updated versions 
can be found at https://cdn.hno.org/media/publika-
tionen/minimal_standards_for_AMEI_v1.0.xlsx and 
https://www.dga-ev.com/fachausschuesse/)).
Post-Op Procedures: Post-operative AC and BC thresh-
olds should be reported together with the pre-op pure-
tone audiometry data for at least the implanted ear about 
6 months after device activation. 
Speech Audiometry
Pre-Op Procedures: The patient’s speech perception 
capability should be estimated by pre-op speech audiom-
etry using headphones or insert earphones on both sides 
separately. The minimum standard would be to report 
the WRS for monosyllabic words in percent correct at a 
fixed sound pressure level (SPL) of 65 and 80 dB SPL. If 
the patient only achieves poor word recognition  < 60 
WRS (% correct) [Martin, 2012] at 80 dB SPL, the sound 
pressure level should be adjusted in order to find and re-
port the maximum WRS (WRSmax1) [Hoppe et al., 2014].
Sound Field Thresholds
Pre-Op Procedures: Sound field thresholds with nar-
row band noise or warble tones must be reported from 
250 Hz to 8 kHz (0.25, 0.5, 1, 2, 4, 6, and 8 kHz) unilater-
ally for the implanted ear with exclusion of the contralat-
eral ear. We suggest plugging and muffling on the contra-
lateral ear. However, our experience shows that the at-
tenuation achieved by this measure is limited to 
approximately 30 dB (0.5 kHz) to 40 dB (1–4 kHz). Spe-
cifically, in asymmetric hearing loss, great care is advised 
to avoid erroneous results and we suggest masking (if 
possible) or exclusion of data. The measurements should 
be done in the unaided and if possible aided conditions, 
using a hearing aid that has been previously deemed ad-
equate for the current amount of hearing loss and with 
controlled and optimized fitting (optimized HA). Results 
from hearing aids that are inappropriate for the patient’s 
hearing loss shall not be included in the study.
Post-Op Procedures: Sound field tests with the AMEI 
should be carried out in a similar manner to those per-
formed preoperatively. If there is a change between pre- 
and post-op pure-tone thresholds (AC, BC ≥10 dB) at 
any frequency, the unaided sound field audiometry must 
also be measured and reported. If patients are included in 
data analysis, and thresholds (BC or AC) are not measur-
able, rules for omission or model-based substitution must 
be clearly defined. In raw data files, “not measurable” or 
“not measured” values have to be clearly marked as not 
measured, not measurable or model-base estimates, and 
the limits of the measurement devices have to be provid-
ed. 
Sound Field Speech Audiometry in Quiet
Pre-Op Procedures: The WRS using monosyllabic 
words at a presentation level of 65 dB SPL must be re-
ported in the unaided condition, and if available with an 
optimized HA in the aided condition. The test should be 
performed and reported unilaterally (unaided and aided 
with exclusion of contralateral ear). If 2 hearing aids are 
available, it is recommended, but optional, to report bi-
lateral WRS with both devices.
Post-Op Procedures: The aided WRS with the AMEI 
should be assessed and reported using the same condi-
tions that were used preoperatively, and preferably at the 
same time the sound field thresholds are measured. If 
there is a change between unaided pre- and post-op pure-
tone thresholds, the unaided WRS should also be mea-
sured and reported post-op.
Sound Field Speech Audiometry in Noise
Pre-Op Procedures: For speech in noise testing, we rec-
ommend the application of an adaptive test to determine 
the speech recognition threshold (SRT) in noise (as dB 
SNR [signal-to-noise ratio]) that is, the difference be-
tween the speech presentation and noise level at the point 
the patient achieves 50% speech perception (SRT50). The 
noise level must be held constant at 65 dB SPL while the 
speech level changes. The measurement must be per-
formed unilaterally excluding the contralateral ear, in the 
unaided condition, and optionally also with an optimized 
HA in the aided condition. We recommend a minimum 
standard of S0N0 azimuth, that is, frontal presentation of 
the signal and the noise (from the same speaker).
Depending on the test results, training might be neces-
sary. For example, in the International matrix test (IMT), 
subjects must be acquainted with the speech material and 
the procedure in order to avoid training effects [Wagener, 
1999]. In this case, the presentation of 2 lists is suggested: 
(1) a list at a well-recognized, fixed speech level in quiet 
as an example and (2) in the adaptive mode in noise, start-
ing from an SNR well above SRT50 (e.g., +10 dB SNR) to 
train the procedure [HörTech, 2014]. Other tests may re-
quire different familiarization procedures.
Hey et al. [Hey et al., 2014] reported that an SRT mea-
sured by the OLSA of greater than approximately 2 dB 1Also known as PBmax.
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leads to results with poor reproducibility in cochlear-im-
planted subjects. However, it has to be taken into consid-
eration that users of middle ear implants have a better 
acoustic reserve i.e., better BC threshold than CI users. If 
the SRT50 result is equal to or higher than 5 dB SNR (≥5 
dB SNR), it shall be defined as “not measurable” and 
should be shown as “not measurable” on graphs. How-
ever, in statistical evaluations, it is recommended to as-
sume a fictitious SRT50 value of 5 dB SNR as the best-case 
estimate. In this way, a fictitious best-case estimate SRT50 
of 5 dB SNR is distinguishable from a real SRT50 value (<  5 
dB SNR) that would be measured and recorded as such.
Nevertheless, this procedure is intended to identify es-
timated values and to limit errors in data and statistics 
when a fixed noise presentation level of 65 dB SPL is used. 
The main limitation arises from the fact that patients with 
a certain severity of hearing loss will not be able to hear 
the noise and therefore hearing in quiet instead of hearing 
in noise is determined. The limit for a fixed noise level of 
65 dB SPL can be expected at a hearing loss between 47 
dB HL [Wardenga et al., 2015] and approx. 50 dB HL, as-
suming it is a “hearing loss comparable with attenuation” 
[Plomp, 1978]. Here, we suggest the commonly used 
fixed noise level of 65 dB SPL in combination with the 
limitation described above that covers a broad range of 
hearing losses up to approxately 47 dB HL. However, in 
the future, the range for the determination of SRT50 re-
sults in noise may be extended using higher noise levels 
and we encourage this usage when validated ranges are 
available.
For the German language, the OLSA test (German ver-
sion of the international matrix test (IMT)) can be used. 
Our proposal is easily extendable to other languages, as 
the IMT (http://www.hoertech.de/en/medical-devices/
intma.html) is available for a variety of different languag-
es. Nevertheless, other comparable tests for which refer-
ence data exist may also be used.
Post-Op Procedures: We recommend reporting on the 
monaurally-aided SRT results after an acclimatization 
time of at least 6 months. Because of test-retest and learn-
ing effects as well as for better comparison, it is useful to 
perform the unaided test again and report these results as 
well.
Pure Tone Average, Functional and Effective Gain
There are inconsistencies in the literature regarding 
the relevant frequencies used to calculate the pure tone 
average (PTA; American Academy of Otolaryngology 
Committee on Hearing and Equilibrium, 1979; Bruch-
hage et al., 2017; Dobie, 2011). To provide a common 
foundation, we recommend the mean threshold of four 
frequencies with octave steps from 0.5, 1, 2 and 4 kHz to 
be used for the PTA (PTA4).
The functional gain (FG) is defined as the mean differ-
ence between unaided and aided thresholds. It is a helpful 
tool to give a quick impression about the hearing benefit 
provided by hearing devices, but it does not contain any 
information about the frequency characteristics and the 
aided hearing level. Therefore, we encourage reporting of 
both the FG and aided thresholds. For calculation of the 
FG, we recommend using the PTA4 (0.5, 1, 2, 4 kHz) to 
compare the unaided and aided sound field thresholds. 
Although the FG is helpful to describe the real-life pa-
tient benefit, since it describes the effect of the device, it 
cannot be effectively used for the technical characteriza-
tion of the device, as AMEIs (and bone conduction de-
vices) may be used to provide the sound stimulus directly 
to the cochlea (e.g. bone conduction devices and AMEI 
for conductive and mixed hearing loss). Here, we encour-
age the use of effective gain (EG), which is the difference 
between aided sound-field threshold and BC threshold 
that describes the amplification relative to the sensori-
neural hearing loss and is independent of air-bone-gaps. 
The data reported according to this standard (Table 1) 
includes all necessary data to calculate the EG in the range 
of 0.5 to 6.0 kHz. If publication of the EG is desired, we 
recommend reporting on the frequency-specific or at 
least the average (0.5, 1, 2, 4 kHz) EG to enable better 
comparison between devices and coupling options. 
Follow-Up Time
The minimum follow-up time after device activation 
is 12 months. For reporting purposes, we recommend 
presenting data from at least 6 months post-activation. 
Data reported as long-term results should be collected 
from at least 12 months post-activation. To avoid mea-
surement failures that can result from too much time 
passing between pre- and post-op visits, it is recommend-
able (if possible) to report the unaided results from the 
same visit as the one the aided results were collected from. 
Safety Outcomes
Pre-Op Procedures: Usually, safety considerations cor-
respond to good clinical practice and are not relevant for 
reporting purposes. However, if a patient does not fulfill 
the inclusion criteria for the intended therapy, the reason 
for device selection as well as off-label use should be men-
tioned.
Post-Op Procedures: The minimal standard for the 
evaluation of clinical safety is the comparison of BC 
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thresholds in the implanted ear to the pre-op assessed BC 
thresholds. Any adverse event (AE) occurring due to the 
therapy must be reported by at least 6 months following 
the surgery. All complications and revision surgeries 
should be reported and marked as therapy-related or not. 
The absence of complications or AEs and their resolution 
during the study period should also be clearly declared in 
the report.
Subjective Outcomes
To assess subjective outcomes, we recommend using 
patient-reported outcome measures, as they are an im-
portant diagnostic element in audiology.
The group of experts discussed the advantages and dis-
advantages of both hearing-specific, patient-reported 
outcome measures, for example, the Abbreviated Profile 
of Hearing Aid Benefit (APHAB) and the International 
Outcome Inventory for Hearing Aids (IOI-HA) as well as 
generic QoL questionnaires, for example, the Health Util-
ity Index (HUI) Mk 2 and 3, the RAND 36-item Short 
Form Health Survey (SF-36), and the Glasgow Benefit In-
ventory (GBI).
The criteria and rationale we used were as follows: (1) 
each questionnaire should include hearing-specific ques-
tions and be validated, (2) the questionnaire should be free 
of charge as financial burden can pose a barrier to the im-
plementation of a questionnaire in a study, (3) the number 
of questions and thus the time required to complete the 
questionnaire should be reasonably small and (4) the 
questionnaire should be available in multiple languages.
The APHAB [Cox, 1997; Cox and Alexander, 1995] is 
a validated self-report questionnaire that is used to quan-
tify the impact of a hearing problem on an individual’s 
daily life. Originally the APHAB was used in English-
speaking (American) adults to evaluate their communi-
cation with other people or perceived difficulty with 
sound recognition in various conditions. It is a useful tool 
for quantifying the disability associated with hearing loss 
and the reduction of the disability with amplification 
[House et al., 2010]. It is a hearing disability-specific 
questionnaire that assesses auditory functioning with 24 
items scored in four 6-item subscales. It produces scores 
for unaided and aided conditions, and benefit is calcu-
lated by comparing the patient’s reported difficulty in the 
unaided condition with their difficulty while using ampli-
fication. In Germany, the APHAB is regularly used for 
hearing aid fitting [Lohler et al., 2016; Lohler et al., 2012]. 
This free-of-charge questionnaire has been translated 
into 20 languages. In a study with 224 German-speaking 
patients, Löhler et al. [Lohler et al., 2010] compared the 
APHAB outcome measured pre- and post-fitting with the 
US (English speaking) norm. They concluded that pa-
tients fitted in a German ENT practice score similarly to 
patients fitted by audiologists in the United States. The 
APHAB was selected as the minimum reporting standard 
to assess subjective benefit.
Since the patient should answer the questions based on 
his/her everyday experience (to minimize bias), it is im-
portant that the patient understands how to complete the 
questionnaire and has ample time to do so before under-
going any audiological tests. This is normally about 10 
min or less. Since the questionnaire contains information 
regarding unaided and aided performance as well as hear-
ing benefit, if the patient completes it both pre- as well as 
post-operatively, it provides a sensitive instrument to de-
tect the benefit of the intervention [de Almeida and Ta-
guchi, 2004]. In addition to the audiological evaluation, 
the post-op subjective benefit evaluation should be per-
formed in the presence of stable audiological results about 
6 months after device activation or one month after a sta-
ble fitting, depending on which occurs first.
Considering this, we recommend assessing subjective 
satisfaction preoperatively with a hearing aid (in the ear 
to be implanted) and postoperatively with the AMEI us-
ing the APHAB 6 and 12 months after the patient’s first 
fitting.
Discussion
In recent years, AMEI have extended the range of 
treatment options for sensorineural and mixed hearing 
loss significantly, and they have helped to provide better 
surgical solutions for patients with previously insufficient 
audiological rehabilitation. Although they overlap in in-
dication ranges with CI and conventional hearing aids, 
they are in a class of their own that shares many properties 
with these other devices as well as many differences. For 
example, the level of invasiveness is comparable to CIs, 
but in terms of the amount of residual hearing required 
for sufficient benefit, they may be better compared to 
HAs. Minimal outcome measurements used for CI [Kle-
ine Punte and Van de Heyning, 2013] or intended for the 
full range of hearing loss treatments [Gurgel et al., 2012] 
do not cover the relevant AMEI-specific properties and 
are therefore inappropriate to use with AMEIs. Tysome 
et al. [Tysome et al., 2010] concludes that the overall qual-
ity of AMEI studies is moderate to poor because of a lack 
of comparison with conventional hearing aids. Further-
more, pooling data on an international or multicentre ba-
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sis to extend the statistical basis is not possible due to the 
large heterogeneity of tests and settings used to report 
audiological results, AEs and QoL measures. Indepen-
dent meta-analyses are required to clinically verify indi-
cation ranges, enable cross-site comparison, determine 
long-term results and enable comparisons between de-
vice classes to decide about reimbursement strategies.
The intention of the minimal reporting standards pro-
posed here was to define an essential core data set that is 
both currently available as well as easily implemented 
into clinical routine. They should also be able to be ex-
tended according to the specific needs of the investigated 
application, to enable comparison and pooling of results 
to create convincing evidence in meta-analyses.
Although developed initially for the German language, 
the proposal seeks to minimize language-specific ele-
ments to make it easily extendable to other languages. For 
the suggested monosyllabic test, reference data exists in 
many languages and the international matrix test pro-
posed is available in a variety of languages as well (http://
www.hoertech.de/en/medical-devices/intma.html). 
However, comparability may be difficult or impossible 
for some language groups such as tonal languages and 
this has to be addressed in future investigations.
As with any complex intervention, the treatment with 
AMEIs encompasses a broad range of relevant informa-
tion including the indication, the surgical intervention, 
necessary after-care and long-term follow up. However, 
the minimal reporting guidelines focus on the medical 
aspects relevant for the evaluation of the benefit of AMEI 
treatment. 
In the future, it will be of interest to assess and report 
in long-term follow-ups on how long the AMEI hearing 
rehabilitation procedure leads to a sufficient hearing out-
come without medical problems, or the disease-free-sur-
vival, given by technical and medical constraints. Equally 
important are the audiological aspects, such as what per-
centage of patients still benefit from the procedure/device 
after 3, 5 or 10 years, or conversely, how many patients 
eventually required a different solution (e.g., a cochlear 
implant).
The audiological measurements suggested here were 
intended to be feasible with standard calibrated equip-
ment in a limited timeframe, utilizing the common exper-
tise of clinical personnel conducting routine examina-
tions. AC and BC pure tone thresholds obtained at least 
at the most speech-relevant frequencies should make it 
possible to trace the impact of the intervention and long-
term results. Sound field thresholds should allow for 
comparison to HAs and can be used to determine “func-
tional” and “effective gain.” The maximum monosyllabic 
WRS for phonemically balanced words (WRSmax) via 
headphones serves as an important preoperative indica-
tor for later success in assessing cochlear reserve and dead 
regions [Hoppe et al., 2015]. The WRS has to be measured 
at a fixed sound pressure level (65 dB) to measure speech 
perception improvements induced by AMEIs. Reporting 
WRS measured at a fixed-sensation level of 40 dB above 
SL, as suggested by Gurgel et al. [Gurgel et al., 2012]) 
would already show a ceiling effect before implantation 
and would therefore not be sensitive for AMEI-induced 
improvement and would not allow for a parametric mea-
surement of hearing improvement [Mueller et al., 2017]. 
Furthermore, the use of a fixed SPL for WRS measure-
ments would allow sufficient sample size estimation for 
prospective trials. Speech intelligibility in quiet and noise 
is required with at least frontal sound presentation (S0N0). 
For measurement of special acoustic processing features 
of audio processors, the use of further spatially separated 
sound sources is advised. 
We propose using the APHAB to evaluate subjective 
benefit with AMEIs. Administration of the APHAB before 
and after hearing aid fitting proved to be a valuable and 
sensitive method to detect the benefit of the intervention 
[de Almeida and Taguchi, 2004]. One of its advantages is 
that in most analyses, significant relationships between 
audiometric data and at least 3 of the 4 APHAB subscales 
that reflect speech communication (Ease of communica-
tion, Reverberation, Background noise) can be found 
[Löhler, 2017]. The APHAB has been used as a subjective 
assessment scale in several studies on middle ear implan-
tation [Fraysse et al., 2001; Jenkins et al., 2004; Lenarz et 
al., 2001; Luetje et al., 2002; Todt et al., 2002; Uziel et al., 
2003]. In these studies, comparisons were made between 
APHAB scores obtained before implantation, while the 
patient was still using his conventional hearing aids and 
those obtained after implantation. In general, significant 
changes have been reported, which indicates that implant-
ed patients experience improvements with their AMEI 
compared to their conventional hearing aid. However, it 
should be noted that the level of commitment involved in 
choosing to undergo an invasive treatment might bias the 
outcomes. Cox and Alexander reported reference APHAB 
scores obtained in a group of patients with moderate-to-
severe hearing loss fitted with conventional linear hearing 
aids [Cox and Alexander, 1995].
As more specific QoL measures and patient-reported 
outcomes will be developed and internationally validated 
in the future, these will likely need to be added to the 
minimal reporting outcome data sets.
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